A randomized double-blind parallel-group flexible-dose study exploring the neurocognitive effect of Sertindole verses Quetiapine in patients with schizophrenia using the MATRICS Consensus Cognitive Battery (MCCB)
A
Anantha Shekhar, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Not Recruiting
18 years - 100 years
All
Phase
N/A
1 Location
Brief description of study
No Description Available
Detailed description of study
No Description Available
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Schizophrenia
-
Age: 18 years - 100 years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 0804-05
